Literature DB >> 18930379

A systematic method for estimating individual responses to treatment with antipsychotics in CATIE.

Edwin J C G van den Oord1, Daniel E Adkins, Joseph McClay, Jeffrey Lieberman, Patrick F Sullivan.   

Abstract

OBJECTIVE: In addition to comparing drug treatment groups, the wealth of genetic and clinical data collected in the Clinical Antipsychotic Trials of Intervention Effectiveness study offers tremendous opportunities to study individual differences in response to treatment with antipsychotics. A major challenge, however, is how to estimate the individual responses to treatments. For this purpose, we propose a systematic method that condenses all information collected during the trials in an optimal, empirical fashion.
METHODS: Our method comprises three steps. First, we test how to best model treatment effects over time. Next, we screen many covariates to select those that will further improve the precision of the individual treatment effect estimates which, for example, improves power to detect predictors of individual treatment response. Third, Best Linear Unbiased Predictors (BLUPs) of the random effects are used to estimate for each individual a treatment effect based on the model empirically indicated to best fit the data. We illustrate our method for the Positive and Negative Syndrome Scale (PANSS).
RESULTS: A model assuming it takes on average about 30 days for a treatment to exert an effect that will then remain about the same for the rest of the trial showed the best fit to the data. Of all screened covariates, only two improved the precision of the individual treatment effect estimates. Finally, correlations between drug effects and PANSS scales suggested that in CATIE it cannot be recommended to simply combine treatment effects across drugs (e.g. to study common drug mechanisms), but it is sensible to study how a given drug affects multiple symptom dimensions.
CONCLUSIONS: We demonstrate that treatment effects can be estimated in a way that condenses all information collected in an optimal, empirical fashion. We expect the proposed method to be valuable for other clinical outcomes in CATIE and potentially other clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18930379      PMCID: PMC2652489          DOI: 10.1016/j.schres.2008.09.009

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  19 in total

Review 1.  Pharmacologic treatment of schizophrenia.

Authors:  J M Kane
Journal:  Biol Psychiatry       Date:  1999-11-15       Impact factor: 13.382

2.  Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected.

Authors:  Ofer Agid; Shitij Kapur; Tamara Arenovich; Robert B Zipursky
Journal:  Arch Gen Psychiatry       Date:  2003-12

3.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

4.  Genomewide association for schizophrenia in the CATIE study: results of stage 1.

Authors:  P F Sullivan; D Lin; J-Y Tzeng; E van den Oord; D Perkins; T S Stroup; M Wagner; S Lee; F A Wright; F Zou; W Liu; A M Downing; J Lieberman; S L Close
Journal:  Mol Psychiatry       Date:  2008-03-18       Impact factor: 15.992

5.  Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment.

Authors:  H Y Meltzer; G Okayli
Journal:  Am J Psychiatry       Date:  1995-02       Impact factor: 18.112

6.  Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.

Authors:  Richard S E Keefe; Richard C Mohs; Robert M Bilder; Philip D Harvey; Michael F Green; Herbert Y Meltzer; James M Gold; Mary Sano
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

7.  The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Authors:  T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Matthew J Byerly; Ira D Glick; Jose M Canive; Mark F McGee; George M Simpson; Michael C Stevens; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

8.  A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity.

Authors:  Timothy M Frayling; Nicholas J Timpson; Michael N Weedon; Eleftheria Zeggini; Rachel M Freathy; Cecilia M Lindgren; John R B Perry; Katherine S Elliott; Hana Lango; Nigel W Rayner; Beverley Shields; Lorna W Harries; Jeffrey C Barrett; Sian Ellard; Christopher J Groves; Bridget Knight; Ann-Marie Patch; Andrew R Ness; Shah Ebrahim; Debbie A Lawlor; Susan M Ring; Yoav Ben-Shlomo; Marjo-Riitta Jarvelin; Ulla Sovio; Amanda J Bennett; David Melzer; Luigi Ferrucci; Ruth J F Loos; Inês Barroso; Nicholas J Wareham; Fredrik Karpe; Katharine R Owen; Lon R Cardon; Mark Walker; Graham A Hitman; Colin N A Palmer; Alex S F Doney; Andrew D Morris; George Davey Smith; Andrew T Hattersley; Mark I McCarthy
Journal:  Science       Date:  2007-04-12       Impact factor: 47.728

9.  A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants.

Authors:  Laura J Scott; Karen L Mohlke; Lori L Bonnycastle; Cristen J Willer; Yun Li; William L Duren; Michael R Erdos; Heather M Stringham; Peter S Chines; Anne U Jackson; Ludmila Prokunina-Olsson; Chia-Jen Ding; Amy J Swift; Narisu Narisu; Tianle Hu; Randall Pruim; Rui Xiao; Xiao-Yi Li; Karen N Conneely; Nancy L Riebow; Andrew G Sprau; Maurine Tong; Peggy P White; Kurt N Hetrick; Michael W Barnhart; Craig W Bark; Janet L Goldstein; Lee Watkins; Fang Xiang; Jouko Saramies; Thomas A Buchanan; Richard M Watanabe; Timo T Valle; Leena Kinnunen; Gonçalo R Abecasis; Elizabeth W Pugh; Kimberly F Doheny; Richard N Bergman; Jaakko Tuomilehto; Francis S Collins; Michael Boehnke
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

10.  A variant in CDKAL1 influences insulin response and risk of type 2 diabetes.

Authors:  Valgerdur Steinthorsdottir; Gudmar Thorleifsson; Inga Reynisdottir; Rafn Benediktsson; Thorbjorg Jonsdottir; G Bragi Walters; Unnur Styrkarsdottir; Solveig Gretarsdottir; Valur Emilsson; Shyamali Ghosh; Adam Baker; Steinunn Snorradottir; Hjordis Bjarnason; Maggie C Y Ng; Torben Hansen; Yu Bagger; Robert L Wilensky; Muredach P Reilly; Adebowale Adeyemo; Yuanxiu Chen; Jie Zhou; Vilmundur Gudnason; Guanjie Chen; Hanxia Huang; Kerrie Lashley; Ayo Doumatey; Wing-Yee So; Ronald C Y Ma; Gitte Andersen; Knut Borch-Johnsen; Torben Jorgensen; Jana V van Vliet-Ostaptchouk; Marten H Hofker; Cisca Wijmenga; Claus Christiansen; Daniel J Rader; Charles Rotimi; Mark Gurney; Juliana C N Chan; Oluf Pedersen; Gunnar Sigurdsson; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2007-04-26       Impact factor: 38.330

View more
  27 in total

1.  The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment.

Authors:  Thomas G Schulze; Martin Alda; Mazda Adli; Nirmala Akula; Raffaella Ardau; Elise T Bui; Caterina Chillotti; Sven Cichon; Piotr Czerski; Maria Del Zompo; Sevilla D Detera-Wadleigh; Paul Grof; Oliver Gruber; Ryota Hashimoto; Joanna Hauser; Rebecca Hoban; Nakao Iwata; Layla Kassem; Tadafumi Kato; Sarah Kittel-Schneider; Sebastian Kliwicki; John R Kelsoe; Ichiro Kusumi; Gonzalo Laje; Susan G Leckband; Mirko Manchia; Glenda Macqueen; Takuya Masui; Norio Ozaki; Roy H Perlis; Andrea Pfennig; Paola Piccardi; Sara Richardson; Guy Rouleau; Andreas Reif; Janusz K Rybakowski; Johanna Sasse; Johannes Schumacher; Giovanni Severino; Jordan W Smoller; Alessio Squassina; Gustavo Turecki; L Trevor Young; Takeo Yoshikawa; Michael Bauer; Francis J McMahon
Journal:  Neuropsychobiology       Date:  2010-05-08       Impact factor: 2.328

2.  Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study.

Authors:  Timothy L Ramsey; Qian Liu; Bill W Massey; Mark D Brennan
Journal:  Schizophr Res       Date:  2013-07-23       Impact factor: 4.939

3.  Replication of SULT4A1-1 as a pharmacogenetic marker of olanzapine response and evidence of lower weight gain in the high response group.

Authors:  Timothy L Ramsey; Qian Liu; Mark D Brennan
Journal:  Pharmacogenomics       Date:  2014-05       Impact factor: 2.533

4.  Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis.

Authors:  Todd S Woodward; Kwanghee Jung; Geoffrey N Smith; Heungsun Hwang; Alasdair M Barr; Ric M Procyshyn; Sean W Flynn; Mark van der Gaag; William G Honer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-15       Impact factor: 5.270

5.  A genomewide association study of citalopram response in major depressive disorder-a psychometric approach.

Authors:  Daniel E Adkins; Karolina Aberg; Joseph L McClay; John M Hettema; Susan G Kornstein; József Bukszár; Edwin J C G van den Oord
Journal:  Biol Psychiatry       Date:  2010-09-15       Impact factor: 13.382

6.  Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication.

Authors:  Nathan L Hutcheson; David G Clark; Mark S Bolding; David M White; Adrienne C Lahti
Journal:  Psychiatry Res       Date:  2013-10-22       Impact factor: 3.222

7.  Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.

Authors:  Shaunna L Clark; Renan P Souza; Daniel E Adkins; Karolina Aberg; József Bukszár; Joseph L McClay; Patrick F Sullivan; Edwin J C G van den Oord
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

8.  Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.

Authors:  D E Adkins; K Aberg; J L McClay; J Bukszár; Z Zhao; P Jia; T S Stroup; D Perkins; J P McEvoy; J A Lieberman; P F Sullivan; E J C G van den Oord
Journal:  Mol Psychiatry       Date:  2010-03-02       Impact factor: 15.992

9.  Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.

Authors:  J L McClay; D E Adkins; K Aberg; S Stroup; D O Perkins; V I Vladimirov; J A Lieberman; P F Sullivan; E J C G van den Oord
Journal:  Mol Psychiatry       Date:  2009-09-01       Impact factor: 15.992

10.  Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia.

Authors:  Adrienne C Lahti; Martin A Weiler; Henry H Holcomb; Carol A Tamminga; Karen L Cropsey
Journal:  Neuropsychopharmacology       Date:  2009-08-12       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.